معرفی
Dr. Stephen Dobbin is an Honorary Clinical Research Fellow at the University of Glasgow, affiliated with the School of Cardiovascular & Metabolic Health and the Cardiology Department at Queen Elizabeth University Hospital. His research focuses on cardio-oncology, cardiotoxicity of cancer therapies, hypertension, and heart failure. He has contributed to studies on vascular endothelial growth factor (VEGF) inhibitors, renal outcomes in cancer patients, and the effects of anti-cancer drugs on cardiovascular systems. His work includes systematic reviews, meta-analyses, and clinical trials exploring biomarkers, therapeutic strategies, and patient outcomes. He has co-authored over 15 articles and book chapters since 2015, emphasizing multidisciplinary approaches to managing cardio-oncology challenges and drug-induced cardiac toxicity.
Key areas of research include: (1) cardiotoxic effects of angiogenesis inhibitors and VEGF therapies, (2) hypertension and renal dysfunction in cancer patients, (3) heart failure comorbidities with cancer, and (4) imaging techniques (e.g., cardiac MRI) for early detection of therapy-induced cardiac injury. His recent work (2025) highlights multimodal assessment of VEGF inhibitor cardiotoxicity.
Dr. Dobbin collaborates with institutions like the Queen Elizabeth University Hospital and international teams on clinical trials and translational research. He has not been explicitly mentioned to hold formal grants or lead specific labs, but his contributions align with broader cardiovascular research initiatives at the University of Glasgow.
